Top

International Journal of Colorectal Disease

Published in:

01-02-2017 | Original Article

Combining aneuploidy and dysplasia for colitis’ cancer risk assessment outperforms current surveillance efficiency: a meta-analysis

Authors: Rüdiger Meyer, Sandra Freitag-Wolf, Silke Blindow, Jürgen Büning, Jens K. Habermann

Published in: International Journal of Colorectal Disease | Issue 2/2017

Abstract

Purpose

Cancer risk assessment for ulcerative colitis patients by evaluating histological changes through colonoscopy surveillance is still challenging. Thus, additional parameters of high prognostic impact for the development of colitis-associated carcinoma are necessary. This meta-analysis was conducted to clarify the value of aneuploidy as predictor for individual cancer risk compared with current surveillance parameters.

Methods

A systematic web-based search identified studies published in English that addressed the relevance of the ploidy status for individual cancer risk during surveillance in comparison to neoplastic mucosal changes. The resulting data were included into a meta-analysis, and odds ratios (OR) were calculated for aneuploidy or dysplasia or aneuploidy plus dysplasia.

Results

Twelve studies addressing the relevance of aneuploidy compared to dyplasia were comprehensively evaluated and further used for meta-analysis. The meta-analysis revealed that aneuploidy (OR 5.31 [95 % CI 2.03, 13.93]) is an equally effective parameter for cancer risk assessment in ulcerative colitis patients as dysplasia (OR 4.93 [1.61, 15.11]). Strikingly, the combined assessment of dysplasia and aneuploidy is superior compared to applying each parameter alone (OR 8.99 [3.08, 26.26]).

Conclusions

This meta-analysis reveals that aneuploidy is an equally effective parameter for individual cancer risk assessment in ulcerative colitis as the detection of dysplasia. More important, the combined assessment of dysplasia and aneuploidy outperforms the use of each parameter alone. We suggest image cytometry for ploidy assessment to become an additional feature of consensus criteria to individually assess cancer risk in UC.

Crohn UB, Rosenberg H (1925) The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 170:220–228CrossRef

Campbell S, Ghosh S (2002) Ulcerative colitis and colon cancer: strategies for cancer prevention. Dig Dis 20(1):38–48 doi: ddi20038 [pii]PubMedCrossRef

Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48(4):526–535PubMedPubMedCentralCrossRef

Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2(12):1088–1095CrossRef

Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19(4):789–799. doi:10.1097/MIB.0b013e31828029c0 PubMedCrossRef

Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M (2012) Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143(2):375–381 . doi:10.1053/j.gastro.2012.04.016e371; quiz e313-374PubMedCrossRef

Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F (2012) Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 143(2):382–389. doi:10.1053/j.gastro.2012.04.054 PubMedCrossRef

Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC et al (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14(11):931–968PubMedCrossRef

Seril DN, Liao J, Yang GY, Yang CS (2003) Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24(3):353–362PubMedCrossRef

10.

Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138(6):2101–2114 e 2105. doi: S0016-5085(10)00176-9 [pii] 053/j.gastro.2010.01.058PubMedCrossRef

11.

Stange EF, Travis SP (2008) The European consensus on ulcerative colitis: new horizons? Gut 57(8):1029–1031 doi: gut.2007.146761 [pii] 1136/gut.2007.146761PubMedCrossRef

12.

Itzkowitz SH, Present DH (2005) Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11(3):314–321 doi: 00054725-200503000-00012 [pii]PubMedCrossRef

13.

Carter MJ, Lobo AJ, Travis SP (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53(Suppl 5):V1–16. doi:10.1136/gut.2004.043372 53/suppl_5/v1 [pii]PubMedPubMedCentralCrossRef

14.

Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124(2):544–560. doi:10.1053/gast.2003.50044 S0016508502158951 [pii]PubMedCrossRef

15.

Kornbluth A, Sachar DB (2004) Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, practice parameters committee. Am J Gastroenterol 99(7):1371–1385. doi:10.1111/j.1572-0241.2004.40036.x AJG40036 [pii]PubMedCrossRef

16.

Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB (2007) Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 65(7):998–1004 doi: S0016-5107(06)02950-6 [pii] 1016/j.gie.2006.09.025PubMedCrossRef

17.

Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Oldenburg B, Samsom M (2008) High frequency of early colorectal cancer in inflammatory bowel disease. Gut 57(9):1246–1251 doi: gut.2007.143453 [pii] 1136/gut.2007.143453PubMedCrossRef

18.

Meyer R, Laubert T, Sommer M, Benecke C, Lehnert H, Fellermann K, Bruch HP, Keck T, Thorns C, Habermann JK, Buning J (2015) Colorectal neoplasia in IBD-a single-center analysis of patients undergoing proctocolectomy. Int J Color Dis 30(6):821–829. doi:10.1007/s00384-015-2217-7 CrossRef

19.

Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH (1994) Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107(4):934–944 doi: S0016508594003082 [pii]PubMedCrossRef

20.

Lynch DA, Lobo AJ, Sobala GM, Dixon MF, Axon AT (1993) Failure of colonoscopic surveillance in ulcerative colitis. Gut 34(8):1075–1080PubMedPubMedCentralCrossRef

21.

Riddell RH (1998) How reliable/valid is dysplasia in identifying at-risk patients with ulcerative colitis? J Gastrointest Surg 2(4):314–317 doi: S1091-255X(98)80068-1 [pii]PubMedCrossRef

22.

Dobbins WO 3rd (1977) Current status of the precancer lesion in ulcerative colitis. Gastroenterology 73(6):1431–1433PubMed

23.

Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103(5):1611–1620PubMedCrossRef

24.

Collins PD, Mpofu C, Watson AJ, Rhodes JM (2006) Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2:CD000279. doi:10.1002/14651858.CD000279.pub3

25.

Bernstein CN, Weinstein WM, Levine DS, Shanahan F (1995) Physicians’ perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 90(12):2106–2114PubMed

26.

Eaden JA, Ward BA, Mayberry JF (2000) How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 51(2):123–128 doi: S0016510700310124 [pii]PubMedCrossRef

27.

Dixon MF, Brown LJ, Gilmour HM, Price AB, Smeeton NC, Talbot IC, Williams GT (1988) Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 13(4):385–397PubMedCrossRef

28.

Odze RD, Tomaszewski JE, Furth EE, Feldman MD, Diallo R, Poremba C, Becker I, Hoefler H, Goldblum JR, Rybicki LA, Alsaigh N, Fogt F (2006) Variability in the diagnosis of dysplasia in ulcerative colitis by dynamic telepathology. Oncol Rep 16(5):1123–1129PubMed

29.

Melville DM, Jass JR, Shepherd NA, Northover JM, Capellaro D, Richman PI, Lennard-Jones JE, Ritchie JK, Andersen SN (1988) Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology 95(3):668–675 doi:S001650858800280X [pii]PubMedCrossRef

30.

Eaden J, Abrams K, McKay H, Denley H, Mayberry J (2001) Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 194(2):152–157. doi:10.1002/path.876 [pii] 1002/path.876PubMedCrossRef

31.

Dundas SA, Kay R, Beck S, Cotton DW, Coup AJ, Slater DN, Underwood JC (1987) Can histopathologists reliably assess dysplasia in chronic inflammatory bowel disease? J Clin Pathol 40(11):1282–1286PubMedPubMedCentralCrossRef

32.

Melville DM, Jass JR, Morson BC, Pollock DJ, Richman PI, Shepherd NA, Ritchie JK, Love SB, Lennard-Jones JE (1989) Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 20(10):1008–1014. doi:10.1016/0046-8177(89)90273-6 PubMedCrossRef

33.

Hammarberg C, Slezak P, Tribukait B (1984) Early detection of malignancy in ulcerative colitis. A flow-cytometric DNA study. Cancer 53(2):291–295PubMedCrossRef

34.

Burum-Auensen E, Deangelis PM, Schjolberg AR, Roislien J, Andersen SN, Clausen OP (2007) Spindle proteins aurora a and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis. J Clin Pathol 60(12):1403–1408 doi: jcp.2006.044305 [pii] 1136/jcp.2006.044305PubMedPubMedCentralCrossRef

35.

Sjoqvist U, Hertervig E, Nilsson A, Duan RD, Ost A, Tribukait B, Lofberg R (2002) Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. Inflamm Bowel Dis 8(4):258–263PubMedCrossRef

36.

Keller R, Foerster EC, Kohler A, Floer B, Winde G, Terpe HJ, Domschke W (2001) Diagnostic value of DNA image cytometry in ulcerative colitis. Dig Dis Sci 46(4):870–878PubMedCrossRef

37.

Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR, Stevens AC, Rubin CE (1992) Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103(5):1602–1610 doi:S0016508592004360 [pii]PubMedCrossRef

38.

Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B (1992) DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 102(4 Pt 1):1149–1154PubMedCrossRef

39.

Porschen R, Molsberger G, Reis C, Borchard F, Reis HE, Eckardt VF, Purrmann J, Hengels KJ, Strohmeyer G (1992) DNA ploidy and dysplasia in ulcerative colitis—interim analysis of a prospective study. Zeitschrift Fur Gastroenterologie 30(12):857–862PubMed

40.

Levine DS, Rabinovitch PS, Haggitt RC, Blount PL, Dean PJ, Rubin CE, Reid BJ (1991) Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. Gastroenterology 101(5):1198–1210 doi:S0016508591003712 [pii]PubMedCrossRef

41.

Meyer KF, Nause SL, Freitag-Wolf S, Kruger S, Bruch HP, Roblick UJ, Habermann JK (2013) Aneuploidy characterizes adjacent non-malignant mucosa of ulcerative colitis-associated but not sporadic colorectal carcinomas: a matched-pair analysis. Scand J Gastroenterol 48(6):679–687. doi:10.3109/00365521.2013.783103 PubMedCrossRef

42.

Grabsch H, Kerr D, Quirke P (2004) Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours? Histopathology 45(4):312–334 doi: HIS1901 [pii] 1111/j.1365-2559.2004.01901.xPubMedCrossRef

43.

Fozard JB, Quirke P, Dixon MF, Giles GR, Bird CC (1986) DNA aneuploidy in ulcerative colitis. Gut 27(12):1414–1418PubMedPubMedCentralCrossRef

44.

Holzmann K, Klump B, Borchard F, Gregor M, Porschen R (2001) Flow cytometric and histologic evaluation in a large cohort of patients with ulcerative colitis: correlation with clinical characteristics and impact on surveillance. Dis Colon rectum 44(10):1446–1455PubMedCrossRef

45.

Sjoqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Lofberg R (2004) Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 24(5B):3121–3127PubMed

46.

Habermann J, Lenander C, Roblick UJ, Kruger S, Ludwig D, Alaiya A, Freitag S, Dumbgen L, Bruch HP, Stange E, Salo S, Tryggvason K, Auer G, Schimmelpenning H (2001) Ulcerative colitis and colorectal carcinoma: DNA-profile, laminin-5 gamma2 chain and cyclin a expression as early markers for risk assessment. Scand J Gastroenterol 36(7):751–758PubMedCrossRef

47.

Lindberg JO, Stenling RB, Rutegard JN (1999) DNA aneuploidy as a marker of premalignancy in surveillance of patients with ulcerative colitis. Br J Surg 86(7):947–950. doi:10.1046/j.1365-2168.1999.01133.x PubMedCrossRef

48.

Karlen P, Young E, Brostrom O, Lofberg R, Tribukait B, Ost K, Bodian C, Itzkowitz S (1998) Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy. Gastroenterology 115(6):1395–1404 doi:S0016508598006015 [pii]PubMedCrossRef

49.

Befrits R, Hammarberg C, Rubio C, Jaramillo E, Tribukait B (1994) DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon rectum 37(4):313–319 discussion 319-320PubMedCrossRef

50.

Rutegard J, Ahsgren L, Stenling R, Roos G (1989) DNA content and mucosal dysplasia in ulcerative colitis. Flow cytometric analysis in patients with dysplastic or indefinite morphologic changes in the colorectal mucosa. Dis Colon rectum 32(12):1055–1059PubMedCrossRef

51.

Rutegard J, Ahsgren L, Stenling R, Roos G (1988) DNA content in ulcerative colitis. Flow cytometric analysis in a patient series from a defined area. Dis Colon rectum 31(9):710–715PubMedCrossRef

52.

Lofberg R, Tribukait B, Ost A, Brostrom O, Reichard H (1987) Flow cytometric DNA analysis in longstanding ulcerative colitis: a method of prediction of dysplasia and carcinoma development? Gut 28(9):1100–1106PubMedPubMedCentralCrossRef

53.

Choi WT, Rabinovitch PS, Wang D, Westerhoff M (2015) Outcome of "indefinite for dysplasia" in inflammatory bowel disease: correlation with DNA flow cytometry and other risk factors of colorectal cancer. Hum Pathol 46(7):939–947. doi:10.1016/j.humpath.2015.03.009 PubMedCrossRef

54.

Auer G, Ono J, Nasiell M, Caspersson T, Kato H, Konaka C, Hayata Y (1982) Reversibility of bronchial cell atypia. Cancer Res 42(10):4241–4247PubMed

55.

Ono J, Auer G, Caspersson T, Nasiell M, Saito T, Konaka C, Kato H, Hayata Y (1984) Reversibility of 20-methylcholanthrene-induced bronchial cell atypia in dogs. Cancer 54(6):1030–1037PubMedCrossRef

56.

Lanigan D, McLean PA, Curran B, Leader M (1993) Comparison of flow and static image cytometry in the determination of ploidy. J Clin Pathol 46(2):135–139PubMedPubMedCentralCrossRef

57.

Bauer TW, Tubbs RR, Edinger MG, Suit PF, Gephardt GN, Levin HS (1990) A prospective comparison of DNA quantitation by image and flow cytometry. Am J Clin Pathol 93(3):322–326PubMedCrossRef

58.

Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH 2nd, Waldman FM (1999) Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 154(6):1825–1830 doi: 1016/S0002-9440(10)65438-7 S0002-9440(10)65438-7 [pii]PubMedPubMedCentralCrossRef

Title: Combining aneuploidy and dysplasia for colitis’ cancer risk assessment outperforms current surveillance efficiency: a meta-analysis
Authors: Rüdiger Meyer
Sandra Freitag-Wolf
Silke Blindow
Jürgen Büning
Jens K. Habermann
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: International Journal of Colorectal Disease / Issue 2/2017
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-016-2684-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Combining aneuploidy and dysplasia for colitis’ cancer risk assessment outperforms current surveillance efficiency: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2017

Evaluation of lymph flow patterns in splenic flexural colon cancers using laparoscopic real-time indocyanine green fluorescence imaging

Laparoscopic versus open distal pancreatectomy—a propensity score-matched analysis from the German StuDoQ|Pancreas registry

Post-operative morbidity, but not mortality, is worsened by operative delay in septic diverticulitis

Impact of incisional negative pressure wound therapy on perineal wound healing after abdominoperineal rectum extirpation

Impact of perioperative hypoglycaemia in subjects with diabetes undergoing colorectal surgery

Insulated-tip knife endoscopic polypectomy for difficult pedunculated colorectal polyps: a prospective pilot study